G-quadruplex, Friend or Foe: The Role of the G-quartet in Anticancer Strategies

Trends Mol Med. 2020 Sep;26(9):848-861. doi: 10.1016/j.molmed.2020.05.002. Epub 2020 May 25.

Abstract

The clinical applicability of G-quadruplexes (G4s) as anticancer drugs is currently being evaluated. Several G4 ligands and aptamers are undergoing clinical trials following the notable examples of quarfloxin and AS1411, respectively. In this review, we summarize the latest achievements and breakthroughs in the use of G4 nucleic acids as both therapeutic tools ('friends', as healing anticancer drugs) and targets ('foes', within the harmful cancer cell), particularly using aptamers and quadruplex-targeted ligands, respectively. We explore the recent research on synthetic G4 ligands toward the discovery of anticancer therapeutics and their mechanism of action. Additionally, we highlight recent advances in chemical and structural biology that enable the design of specific G4 aptamers to be used as novel anticancer agents.

Keywords: G-quadruplex; anticancer strategy; aptamers; cell regulation; drug discovery; ligands.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Antineoplastic Agents / pharmacology*
  • Antineoplastic Agents / therapeutic use*
  • Aptamers, Nucleotide / pharmacology
  • Aptamers, Nucleotide / therapeutic use
  • G-Quadruplexes / drug effects*
  • Humans
  • Ligands
  • Neoplasms / drug therapy*
  • Nucleic Acids / pharmacology
  • Oligodeoxyribonucleotides / pharmacology
  • Oligodeoxyribonucleotides / therapeutic use

Substances

  • AGRO 100
  • Antineoplastic Agents
  • Aptamers, Nucleotide
  • Ligands
  • Nucleic Acids
  • Oligodeoxyribonucleotides